17 Cheuk W, Yuen HK, Chu SY, et al. Lymphadenopathy of IgG4-related sclerosing disease[J]. Am J Surg Pathol, 2008, 32(5): 671-681.
[2]
18 Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease[J]. Mod Pathol, 2009, 22(4): 589-599.
[3]
19 Cornell LD, Chicano SL, Deshpande V, et al. Pseudotumors due to IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatocentric disease[J]. Am J Surg Pathol, 2007, 31(10): 1586-1597.
[4]
20 Nishikawa G, Nakamura K, Yamada Y, et al. Inammatory pseudotumors of the kidney and the lung presenting as immunoglobulin G4-related disease: a case report[J]. J Med Case Rep, 25(5): 480.
[5]
21 Okazaki K, Uchida K, Koyabu MA, et al. IgG4 cholangiopathy - current concept, diagnosis, and pathogenesis[J]. J Hepatol, 2014, 61(3): 690-695.
[6]
15 Hamano H, Arakura N, Muraki T, et al. Prevalence and distribution of extrapancrea lesions complicating autoimmune pancreatitis[J]. J Gastroenterol, 2006, 41(12): 1197-1205.
1 Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders[J]. Ann Rheum Dis, 2009(68): 1310-1315.
[9]
2 Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations[J]. Arthritis Rheum, 2012, 64(10): 3061-3067.
[10]
3 Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012, 22(1): 21-30.
[11]
4 Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis[J]. Dig Dis Sci, 1995, 40(7): 1561-1568.
[12]
5 Inoue D, Zen Y, Abo H, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations[J]. Radiology, 2009(251): 270.
[13]
6 Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease[J]. J Gastroenterol, 2003, 38(10): 982-984.
[14]
7 Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis[J]. N Engl J Med, 2001, 344(10): 732-738.
[15]
8 Kawa S, Ito T, Watanabe T, et al. The utility of Serum IgG4 concentrations as a biomarker[J]. Int J Rheumatol, 2012: 198314.
[16]
9 Kawa S, Sugai S. History of autoimmune pancreatitis and Mikulicz’s disease[J]. Curr Immunol Rev, 2011(7): 137-143.
[17]
10 Kawa S, Fujinaga Y, Ota M, et al. Autoimmune pancreatitis and diagnostic criteria[J]. Curr Immunol Rev, 2011(7): 144-161.
[18]
11 Stone JH, Zen Y, Deshpande V. IgG4-related disease[J]. N Engl J Med, 2012, 366(6): 539-551.
[19]
12 Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details[J]. Mod Rheumatol, 2012, 22(1): 1-14.
[20]
13 Kamisawa T, Okamoto A. IgG4-related sclerosing disease[J]. World J Gastroenterol, 2008, 14(25): 3948-3955.
[21]
14 Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG(4)-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG(4)-related disorders[J]. Ann Rheum Dis, 2009, 68(8): 1310-1315.
